Investors

Media

Welcome to the new Regeneron Newsroom. This newsroom is designed to provide members of the media with easy access to up-to-date information about the Company.

For an e-mail response to questions about Regeneron, please contact us at media@regeneron.com.



View all releases Recent Press Releases

Jun 6, 2016 Regeneron and Sanofi Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
May 31, 2016 Regeneron Presents Positive Interim Data from Phase 2 Proof-of-Concept Study of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia
May 26, 2016 Regeneron Selected by Society for Science & the Public as New Sponsor of the Science Talent Search
May 26, 2016 Words of Support from Public Figures on Regeneron STS Sponsorship
May 25, 2016 Regeneron Announces Important US Prescribing Information Clarification for EYLEA® (aflibercept) Injection
May 11, 2016 Regeneron and Sanofi Genzyme to Present Additional Data from Pivotal Phase 2b Dupilumab Study in Adults with Uncontrolled Persistent Asthma at the American Thoracic Society International Conference
May 5, 2016 Regeneron Reports First Quarter 2016 Financial and Operating Results
May 2, 2016 Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain
Apr 29, 2016 Regeneron Announces Upcoming 2016 Investor Conference Presentations
Apr 15, 2016 Regeneron to Report First Quarter 2016 Financial and Operating Results and Host Conference Call and Webcast on May 5, 2016


Close
Form content here please :)